New York, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight Advancements in gene therapy is a key market driver for Stargardt disease as it offers the potential to target the underlying genetic mutations causing the condition. These therapies aim to restore or replace defective genes, potentially halting or reversing vision loss, attracting significant investment and interest in developing long-term treatments.
DelveInsight’s ' Stargardt Disease Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline Stargardt disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Stargardt disease pipeline domain. Key Takeaways from the Stargardt Disease Pipeline Report DelveInsight’s Stargardt disease pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline Stargardt disease drugs. Key Stargardt disease companies such as Kubota Vision, Nanoscope Therapeutics, Ocugen, Belite Bio, Alkeus Pharmaceuticals, Biophytis, reVision Therapeutics, Inc, IIVERIC bio, Ascidian Therapeutics, Gene Vector Technologies, ReVision Therapeutics, Kiora Pharmaceuticals, and others are evaluating new Stargardt disease drugs to improve the treatment landscape.
Promising pipeline Stargardt disease therapies such as Emixustat, MCO-010, O.
